Developing a gene therapy for heart disease
About the project:
Many heart and skeletal muscle diseases are caused by when the muscle contraction machinery is damaged. In the case of heart muscle, a common result of compromised muscle contraction is a condition called cardiomyopathy.
This study proposes to develop a gene therapy based on a gene called ALPK3 that improves the function of the contraction machinery in a patient’s heart muscle cells, thereby hoping to treat cardiomyopathy.
Lead researcher: A/Prof David Elliott,
Investigators: Prof Enzo Porrello, Dr James McNamara, A/Prof Richard Mills
Tissue of interest: Heart and skeletal muscles
Proudly in partnership with
The Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW, is supported by a Novo Nordisk Foundation grant number NNF21CC0073729